Vertex Pharmaceuticals (VRTX) Change in Accured Expenses (2009 - 2026)

Vertex Pharmaceuticals' Change in Accured Expenses history runs 18 years deep, the most recent figure standing at $70.5 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 46.57% year-over-year to $70.5 million; the TTM figure through Mar 2026 stood at -$94.5 million (down 241.26% YoY), while the FY2025 annual figure was -$116.9 million, down 154.91% from the prior year.
• Change in Accured Expenses was $70.5 million for Q1 2026 at Vertex Pharmaceuticals, up from -$664.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $668.3 million in Q3 2023 to a low of -$664.5 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged $67.0 million across 5 years, with a median of $61.6 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses soared 994.11% in 2022, then slumped 1096.83% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$437.8 million in 2022, then gained by 18.52% to -$356.7 million in 2023, then grew by 10.26% to -$320.1 million in 2024, then slumped by 107.59% to -$664.5 million in 2025, then surged by 110.61% to $70.5 million in 2026.
• The last three Change in Accured Expenses figures came in at $70.5 million (Q1 2026), -$664.5 million (Q4 2025), and $588.8 million (Q3 2025), per Business Quant data.